106 related articles for article (PubMed ID: 10691206)
21. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
Barry AL; Fuchs PC
J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
[TBL] [Abstract][Full Text] [Related]
22. Comparative activities of isepamicin, amikacin, cefepime, and ciprofloxacin alone or in combination with other antibiotics against Stenotrophomonas maltophilia.
Tripodi MF; Andreana A; Sarnataro G; Ragone E; Adinolfi LE; Utili R
Eur J Clin Microbiol Infect Dis; 2001 Jan; 20(1):73-5. PubMed ID: 11245333
[No Abstract] [Full Text] [Related]
23. Antibiotic susceptibility of sulfamethoxazole-trimethoprim resistant Stenotrophomonas maltophilia strains isolated at a tertiary care centre in Hungary.
Juhász E; Pongrácz J; Iván M; Kristóf K
Acta Microbiol Immunol Hung; 2015 Sep; 62(3):295-305. PubMed ID: 26551572
[TBL] [Abstract][Full Text] [Related]
24. Biofilm formation by Stenotrophomonas maltophilia: modulation by quinolones, trimethoprim-sulfamethoxazole, and ceftazidime.
Di Bonaventura G; Spedicato I; D'Antonio D; Robuffo I; Piccolomini R
Antimicrob Agents Chemother; 2004 Jan; 48(1):151-60. PubMed ID: 14693533
[TBL] [Abstract][Full Text] [Related]
25. Antimicrobial susceptibilities of unique Stenotrophomonas maltophilia clinical strains.
Valdezate S; Vindel A; Loza E; Baquero F; Cantón R
Antimicrob Agents Chemother; 2001 May; 45(5):1581-4. PubMed ID: 11302834
[TBL] [Abstract][Full Text] [Related]
26. A multicenter surveillance of antimicrobial resistance on Stenotrophomonas maltophilia in Taiwan.
Wu H; Wang JT; Shiau YR; Wang HY; Lauderdale TL; Chang SC;
J Microbiol Immunol Infect; 2012 Apr; 45(2):120-6. PubMed ID: 22154599
[TBL] [Abstract][Full Text] [Related]
27. Comparative in vitro activity of gemifloxacin.
King A; May J; French G; Phillips I
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():1-12. PubMed ID: 10824026
[TBL] [Abstract][Full Text] [Related]
28. In vitro combination of tigecycline with other antibiotics in Stenotrophomonas maltophilia isolates.
Karamanlıoğlu D; Dizbay M
Turk J Med Sci; 2019 Apr; 49(2):683-686. PubMed ID: 30866602
[TBL] [Abstract][Full Text] [Related]
29. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
[TBL] [Abstract][Full Text] [Related]
30. Stenotrophomonas maltophilia: antimicrobial resistance and molecular typing of an emerging pathogen in a Turkish university hospital.
Gülmez D; Hasçelik G
Clin Microbiol Infect; 2005 Nov; 11(11):880-6. PubMed ID: 16216102
[TBL] [Abstract][Full Text] [Related]
31. Novel variants of the Smqnr family of quinolone resistance genes in clinical isolates of Stenotrophomonas maltophilia.
Gordon NC; Wareham DW
J Antimicrob Chemother; 2010 Mar; 65(3):483-9. PubMed ID: 20071366
[TBL] [Abstract][Full Text] [Related]
32. Activities of 13 quinolones by three susceptibility testing methods against a collection of Haemophilus influenzae isolates with different levels of susceptibility to ciprofloxacin: evidence for cross-resistance.
Pérez-Vázquez M; Román F; Varela MC; Cantón R; Campos J
J Antimicrob Chemother; 2003 Jan; 51(1):147-51. PubMed ID: 12493800
[TBL] [Abstract][Full Text] [Related]
33. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.
Pong A; Thomson KS; Moland ES; Chartrand SA; Sanders CC
J Antimicrob Chemother; 1999 Nov; 44(5):621-7. PubMed ID: 10552978
[TBL] [Abstract][Full Text] [Related]
34. Antimicrobial susceptibility of Stenotrophomonas maltophilia isolates from a Korean tertiary care hospital.
Chung HS; Hong SG; Lee Y; Kim M; Yong D; Jeong SH; Lee K; Chong Y
Yonsei Med J; 2012 Mar; 53(2):439-41. PubMed ID: 22318836
[TBL] [Abstract][Full Text] [Related]
35. Comparative in vitro activity of gatifloxacin against Stenotrophomonas maltophilia and Burkholderia species isolates including evaluation of disk diffusion and E test methods.
Biedenbach DJ; Croco MA; Barrett TJ; Jones RN
Eur J Clin Microbiol Infect Dis; 1999 Jun; 18(6):428-31. PubMed ID: 10442421
[TBL] [Abstract][Full Text] [Related]
36. [Activity of new quinolones against clinical isolates of Corynebacterium species].
Yagüe Guirao G; Martínez-Toldos MC; Mora Peris B; López Domínguez R; Romero Otero M; Muñoz Bellido JL; Segovia Hernández M
Rev Esp Quimioter; 2000 Sep; 13(3):267-70. PubMed ID: 11086275
[TBL] [Abstract][Full Text] [Related]
37. Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia.
Zhang L; Li XZ; Poole K
J Antimicrob Chemother; 2001 Oct; 48(4):549-52. PubMed ID: 11581236
[TBL] [Abstract][Full Text] [Related]
38. Susceptibility to antimicrobial agents of Stenotrophomonas maltophilia isolated from patients with cancer and bacteremia.
Krcmery V; Trupl J; Svetlansky I
Clin Infect Dis; 2001 Jun; 32(11):1656. PubMed ID: 11340542
[No Abstract] [Full Text] [Related]
39. The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents.
Child J; Andrews J; Boswell F; Brenwald N; Wise R
J Antimicrob Chemother; 1995 Jun; 35(6):869-76. PubMed ID: 7559198
[TBL] [Abstract][Full Text] [Related]
40. Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam.
Mojica MF; Papp-Wallace KM; Taracila MA; Barnes MD; Rutter JD; Jacobs MR; LiPuma JJ; Walsh TJ; Vila AJ; Bonomo RA
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784669
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
